MedTrace Logo

Impact of Dialysis Modality on Hepcidin and Iron Metabolism

NCT01723111 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2017-08-22

No results posted yet for this study

Summary

* Dialysis modality may influence the oxidative stress and proinflammatory cytokines in ESRD patients.
* Dialysis modality may affect hepcidin
* Dialysis modality may influence iron and ESA requirements.

Conditions

  • End-stage Renal Disease

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Fresenius Medical Care North America

    collaborator INDUSTRY

  • Kyungpook National University Hospital

    lead OTHER

Principal Investigators

  • Yong-Lim Kim · Division of Nephrology, Department of Internal Medicine, Kyungpook National University School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-02-29
Completion
2016-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01723111 on ClinicalTrials.gov